➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Mallinckrodt
Dow
McKesson
AstraZeneca

Last Updated: June 25, 2021

DrugPatentWatch Database Preview

TYSABRI Drug Profile


Email this page to a colleague

« Back to Dashboard

Recent Clinical Trials for TYSABRI

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Case Comprehensive Cancer CenterPhase 1/Phase 2
South London and Maudsley NHS Foundation TrustPhase 1
King's College LondonPhase 1

See all TYSABRI clinical trials

Recent Litigation for TYSABRI

Identify key patents and potential future biosimilar entrants

PTAB Litigation
PetitionerDate
Swiss Pharma International AG2016-04-18

See all TYSABRI litigation

Pharmacology for TYSABRI
Mechanism of ActionIntegrin Receptor Antagonists

Company Disclosures: US Patents for TYSABRI

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23   Get Started Free University of Iowa Research Foundation (Oakdale, IA) 2009-12-01 RX company
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23   Get Started Free University of Iowa Research Foundation (Iowa City, IA) 2005-01-30 RX company
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23   Get Started Free Fred Hutchinson Cancer Research Center (Seattle, WA) 2015-03-24 RX company
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23   Get Started Free Athena Neurosciences, Inc. (South San Francisco, CA) 2014-01-25 RX company
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23   Get Started Free Elan Pharmaceuticals, Inc. (South San Francisco, CA) 2017-03-07 RX company
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23   Get Started Free Biogen, Inc. (Cambridge, MA) 2020-08-05 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for TYSABRI

These patents were identified by searching patent claims

International Patents for TYSABRI

Country Patent Number Estimated Expiration
Spain 2137354   Get Started Free
South Korea 20110059664   Get Started Free
South Korea 20150083117   Get Started Free
Australia 2017245451   Get Started Free
Turkey 201910848   Get Started Free
World Intellectual Property Organization (WIPO) 2010144513   Get Started Free
World Intellectual Property Organization (WIPO) 2010088548   Get Started Free
>Country >Patent Number >Estimated Expiration

Supplementary Protection Certificates for TYSABRI

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C02649086/01 Switzerland   Get Started Free PRODUCT NAME: TISAGENLECLEUCEL; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66778 18.10.2018
SZ 23/2006 Austria   Get Started Free PRODUCT NAME: NATALIZUMAB
CA 2020 00011 Denmark   Get Started Free PRODUCT NAME: UPADACITINIB; REG. NO/DATE: EU/1/19/1404 20191218
122006000044 Germany   Get Started Free PRODUCT NAME: NATALIZUMAB; REGISTRATION NO/DATE: EU/1/06/346/001 20060627
PA2018502,C1608344 Lithuania   Get Started Free PRODUCT NAME: KLADRIBINAS; REGISTRATION NO/DATE: EU1/17/1212/001-006 20170822
2019C/505 Belgium   Get Started Free PRODUCT NAME: TISAGENLECLEUCEL; AUTHORISATION NUMBER AND DATE: EU/1/18/1297 20180827
PA2019502 Lithuania   Get Started Free PRODUCT NAME: TISAGENLEKLEUCELAS; REGISTRATION NO/DATE: EU/1/18/1297 20180823
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
AstraZeneca
Colorcon
Medtronic
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.